Myriad Genetics, Inc. (MYGN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad Genetics, Inc.” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Myriad Genetics, Inc. has violated federal securities laws.
Investigation Details
On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing “revenue of $196 million declined by 3% year-over-year” and “pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.” Additionally, the Company announced reduced financial guidance for 2025 “reflecting first quarter 2025 results and the current business outlook.” Following this news, Myriad stock dropped on heavy trading volume.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Myriad Genetics, Inc. securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]